Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 43

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 1A
Chunk 43
---
apies and product candidates are subject, in part, to the terms and conditions of assignments and licenses granted to us by others, including Agenus.

•We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.

•We may not be successful in acquiring or in-licensing necessary rights to key technologies or any product candidates we may develop.

•Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights.

•We may not obtain patent term extension (“PTE”) and data exclusivity for any product candidates we may develop.

•We may be unable to protect the confidentiality of our proprietary knowledge.

Risks Related to Employee Matters, Managing Growth, Information Technology and Our Operations

•We may be unable to retain our key executives and to attract, retain and motivate qualified personnel.

•We may encounter difficulties in managing our growth, which could disrupt our operations.

•Our internal computer systems, or those of our third-party vendors, collaborators or other contractors or consultants, may fail or suffer security breaches.

Risks Related to Ownership of Our Common Stock

•A market for our common stock may not be sustained. We may be delisted from the Nasdaq Capital Market if we are unable to comply with Nasdaq Listing Rules.

•Provisions in our organizational documents and Delaware law may have anti-takeover effects.

•Our organizational documents designate courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Risks Related to Our Financial Position and Need for Additional Capital 

We have incurred losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. 

Since inception, we have incurred operating losses associated with our research, clinical development and manufacturing efforts. We have devoted substantially all of our efforts and financial resources in building our iNKT cell platform, identifying our current product candidates, conducting preclinical development and initiating clinical trials of agenT-797. Our net loss was $10.8 million and $22.5 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $144.2 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net 

 18